TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

2004 • 4,992 citations

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

2008 • 3,476 citations

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

2008 • 3,101 citations

KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer

2006 • 2,187 citations

Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

2007 • 1,953 citations

EGFR Antagonists in Cancer Treatment

2008 • 1,940 citations

An Oncogene-Induced DNA Damage Model for Cancer Development

2008 • 1,762 citations

Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor

2004 • 1,709 citations

Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

2008 • 1,579 citations

Cetuximab in the treatment of colorectal cancer.

2004 • 1,501 citations

KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

2008 • 1,432 citations

Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

2007 • 1,111 citations

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

2005 • 948 citations

Systemic Therapy for Colorectal Cancer

2019 • 872 citations

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

2007 • 827 citations

Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti–Epidermal Growth Factor Receptor Antibody Therapies

2007 • 817 citations

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

2007 • 737 citations

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

2007 • 533 citations

PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab

2008 • 461 citations

p53: Guardian of the Genome and Policeman of the Oncogenes

2007 • 429 citations

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

2008 • 391 citations

KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience

2008 • 377 citations

Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab

2007 • 324 citations

Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab

2005 • 324 citations

EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients

2007 • 265 citations

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

2008 • 176 citations

Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study

2008 • 171 citations

Activation of p53-Dependent Growth Suppression in Human Cells by Mutations in PTEN or PIK3CA

2006 • 157 citations

Determination of TP53 Mutation Is More Relevant Than Microsatellite Instability Status for the Prediction of Disease-Free Survival in Adjuvant-Treated Stage III Colon Cancer Patients

2005 • 131 citations

Patterns of EGFR, HER2, TP53, and KRAS Mutations of p14arf Expression in Non–Small Cell Lung Cancers in Relation to Smoking History

2007 • 106 citations

Effect of p53 Status and STAT1 on Chemotherapy-Induced, Fas-Mediated Apoptosis in Colorectal Cancer

2005 • 65 citations

Loss of p53 induces epidermal growth factor receptor promoter activity in normal human keratinocytes

2008 • 45 citations